Abzena announced strong H117 results with overall underlying revenue growth of 46%. This growth resulted from an increase in new customers and expansion of the services provided to existing customers, which starts to demonstrate the value in its integrated service offering. Despite this we have reduced our valuation to £112m, primarily as a result of the discontinuation of simtuzumab (Abzena inside product). However, we note the potential for upside as the company continues to grow its
02 Dec 2016
Integrated service offering demonstrating value
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Integrated service offering demonstrating value
Abzena (ABZA:LON) | 0 0 (-0.9%) | Mkt Cap: 54.0m
- Published:
02 Dec 2016 -
Author:
Dr Linda Pomeroy -
Pages:
4
Abzena announced strong H117 results with overall underlying revenue growth of 46%. This growth resulted from an increase in new customers and expansion of the services provided to existing customers, which starts to demonstrate the value in its integrated service offering. Despite this we have reduced our valuation to £112m, primarily as a result of the discontinuation of simtuzumab (Abzena inside product). However, we note the potential for upside as the company continues to grow its